Modified arabinoxylan from rice bran, MGN-3/Biobran, sensitizes metastatic breast cancer cells to paclitaxel in Vitro

Anticancer Research

Volumn 34, Issue 1, 2014, Pages 81-87

  Ghoneum, Mamdooh ^a   Badr El Din, Nariman K ^b   Ali, Doaa A ^b   El Dein, Mai Alaa ^b  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b Mansoura University   (Egypt)

Author keywords

4T1; Biobran; MCF 7; MGN 3; MTT; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; ARABINOXYLAN; MGN 3; PACLITAXEL; UNCLASSIFIED DRUG; POLYSACCHARIDE MGN3; XYLAN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST METASTASIS; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; NONHUMAN; RICE BRAN; 4T1; BIOBRAN; BREAST TUMOR; CHEMISTRY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; MCF-7; METABOLISM; MGN-3; MTT; PATHOLOGY; RICE; TUMOR CELL CULTURE;

4T1; BIOBRAN; MCF-7; MGN-3; MTT; PACLITAXEL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; DNA DAMAGE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; ORYZA SATIVA; PACLITAXEL; TUMOR CELLS, CULTURED; XYLANS;

EID: 84897026257     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Lorigan P, Lee SM, Betticher D, Woodhead M, Weir D, Hanley S, Hardy C and Thatcher N: Chemotherapy with vincristine/ ifosfamide/carboplatin/etoposide in small cell lung cancer. Semin Oncol 22(3 Suppl 7): 32-41, 1995.
2. Francis PA, Kris MG, Rigas JR, Grant SC and Miller VA: Paclitaxel (Taxol) and docetaxel (Taxotere): Active chemotherapeutic agents in lung cancer. Lung Cancer 12(Suppl 1): S163-172, 1995.
3. Fossella FV, Lee JS, Berille J and Hong WK: Summary of phase II data of docetaxel (Taxotere), an active agent in the first- and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 22(2 Suppl 4): 22-29, 1995.
4. Strauss GM, Lynch TJ, Elias AD, Jacobs C, Kwiatkowski DJ, Shulman LN, Carey RW, Grossbard ML, Jauss S and Sugarbaker DJ: A phase I study of ifosfamide/carboplatin/ etoposide/ paclitaxel in advanced lung cancer. Semin Oncol 22(4 Suppl 9): 70-74, 1995.
5. Singal PK and Iliskovic N: Doxorubicin-induced cardiomyopathy. N Engl J Med 339: 900-905, 1998.
6. Konishi F, Mitsuyama M, Okuda M, Tanaka K, Hasegawa T and Nomoto K: Protective effect of an acidic glycoprotein obtained from culture of Chlorella vulgaris against myelosuppression by 5-fluorouracil. Cancer Immunol Immunother 42: 268-274, 1996.
7. Liu B, Edgerton S, Yang X, Kim A, Ordonez-Ercan D, Mason T, Alvarez K, McKimmey C, Liu N and Thor A: Low-dose dietary phytoestrogen abrogates tamoxifen-associated mammary tumor prevention. Cancer Res 65: 879-886, 2005.
8. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulus S, Katsoulas G, Iconomou G and Kalofonos HP: Vitamin E for prophylaxis against chemotherapy-induced neuropathy-A randomized controlled trial. Neurology 64: 26-31, 2005.
9. Pardini RS: Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. Chem Biol Interact 162: 89-105, 2006.
10. Ghoneum M and Gollapudi S: Modified arabinoxylan rice bran (MGN-3/Biobran) sensitizes human T-cell leukemia cells to death receptor (CD95)-induced apoptosis. Cancer Lett 201: 41-49, 2003.
11. Gollapudi S and Ghoneum M: MGN-3/Biobran, modified arabinoxylan from rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin. Cancer Detect Prev 32: 1-6, 2008.
12. Bang MH, Van Riep T, Thinh NT, Song le H, Dung TT, Van Truong L, Van Don L, Ky TD, Pan D, Shaheen M and Ghoneum M: Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: A three-year randomized clinical trial. Anticancer Res 30: 5145-5151, 2010.
13. Ito E, Takeo S, Kado H, Yamamoto H and Watanabe N: Studies on an antitumor polysaccharide RBS derived from rice bran. I. Preparation, physicochemical properties, and biological activities of RBS. Yakugaku Zasshi 105: 188-193, 1985.
14. Fan H, Morioka T and Iito E: Induction of apoptosis and growth inhibition of cultured human endometrial adenocarcinoma cells (Sawano) by an antitumor lipoprotein fraction of rice bran. Gynecol Oncol 76: 170-175, 2000.
15. Miyoshi N, Koyama Y, Katsuno Y, Hayakawa S and Mita T: Apoptosis induction associated with cell cycle dysregulation by rice bran agglutinin. J Biochem (Tokyo) 130: 799-805, 2001.
16. Liao HF, Chen YY, Yang YC, Wang CS and Chen YJ: Rice (Oryza sativa L.) inhibits growth and induces differentiation of human leukemic U937 cells through activation of peripheral blood mononuclear cells. Food Chem Toxicol 44: 1724-1729, 2006.
17. Ghoneum M: Anti-HIV activity in vitro of MGN-3, an activated arabinoxylan from rice bran. Biochem Biophys Res Commun 243: 25-29, 1998.
18. Ghoneum, M: Enhancement of human natural killer cell activity by modified arabinoxylan from rice bran (MGN-3). Int J Immunother 14: 89-99, 1998.
19. Ghoneum M and Brown J: NK immunorestoration of cancer patients by MGN-3, a modified arabinoxylan rice bran (study of 32 patients followed for up to 4 years). In: Anti-aging Medical Therapeutics, Vol. III. Klatz R and Goldman R (eds.). Marina del Rey, CA: Health Quest Publications, pp. 217-226, 1999.
20. Cholujova D, Jakubikova J, Czako B, Martisova M, Hunakova L, Duraj J, Mistrik M and Sedlak J: MGN-3 arabinoxylan rice bran modulates innate immunity in multiple myeloma patients. Cancer Immunol Immunother 62: 437-445, 2013.
21. Cholujova D, Jakubikova J and Sedlak J: BioBran-augmented maturation of human monocyte-derived dendritic cells. Neoplasma 56: 89-95, 2009.
22. Ghoneum M and Agrawal S: Activation of human monocytederived dendritic cells in vitro by the biological response modifier arabinoxylan rice bran (MGN-3/Biobran). Int J Immunopathol Pharmacol 24: 941-948, 2011.
23. Ghoneum M and Matsuura M: Augmentation of macrophage phagocytosis by modified arabinoxylan rice bran (MGN-3/biobran). Int J Immunopathol Pharmacol 17: 283-292, 2004.
24. Badr El-Din NK, Noaman E and Ghoneum M: In vivo tumor-inhibitory effects of nutritional rice bran supplement MGN-3/Biobran on Ehrlich carcinoma-bearing mice. Nutr Cancer 60: 235-244, 2008.
25. Kuo LJ and Yang LX: Gamma-H2AX-a novel biomarker for DNA double-strand breaks. In Vivo 22: 305-309, 2008.
26. Krishnakumar R and Kraus WL: The PARP side of the nucleus: Molecular actions, physiological outcomes, and clinical targets. Mol Cell 39: 8-24, 2010.
27. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
28. Gligorov J and Lotz JP: Preclinical pharmacology of the taxanes: Implications of the differences. Oncologist 9: 3-8, 2004.
29. Torres K and Horwitz SB: Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 58: 3620-3626, 1998.
30. Pushkarev VM, Starenki DV, Saenko VA, Namba H, Kurebayashi J, Tronko MD and Yamashita S: Molecular mechanism of the effects of low concentrations of taxol in anaplastic thyroid cancer cells. Endocrinology 145: 3143-3152, 2004.
31. Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS and Eckhardt SG: Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol 52: 159-166, 2003.
32. Xu G, Pan J, Martin C and Yeung S-CJ: Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma. J Clin Endocrinol Metab 86: 1769-1777, 2001.
33. Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, Florena A, Di Gaudio F, Di Gesù G and De Maria R: Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63: 6784-6790, 2003.
34. Piñeiro D, Martín ME, Guerra N, Salinas M and González VM: Calpain inhibition stimulates caspase-dependent apoptosis induced by taxol in NIH3T3 cells. Exp Cell Res 313: 369-379, 2007.
35. Guastalla JP, Lhommé C, Dauplat J, Namer M, Bonneterre J, Oberling F, Pouillart P, Fumoleau P, Kerbrat P and Tubiana N. Taxol (paclitaxel) safety in patients with platinum pretreated ovarian carcinoma: An interim analysis of a phase II multicenter study. Ann Oncol 5(Suppl 6): S33-S38, 1994.
36. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y and Saijo N: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1: 599-606, 1995.
37. Endo Y and Kanbayashi H: Modified rice bran beneficial for weight loss of mice as a major and acute adverse effect of cisplatin. Pharmacol Toxicol 92: 300-303, 2003.
38. Jacoby HI, Wnorowski G, Sakata K and Maeda H: The effect of MGN-3 on cisplatin-and adriamycin-induced toxicity in the rat. J Nutraceut Funct Med Foods 3: 3-11, 2001.
39. Takahara K and Sano K: The life prolongation and QOL improvement effect of rice bran arabinoxylan derivative (MGN-3, Bio-Bran) for progressive cancer. Clinical Pharmacol Therapy 14: 267-271, 2004.
40. Kato T and Suzumura Y: Potentiation of antitumor activity of vincristine by the biscoclaurine alkaloid cepharanthine. J Natl Cancer Inst 79: 527-532, 1987.
41. Yamamoto S, Hui PZ, Fukuda Y, Tatsumi K and Mino M: Potentiation of harringtonine cytotoxicity by calcium antagonist diltiazem and biscoclaurine alkaloid cepharanthine in adriamycin-resistant P388 murine leukemia and K562 human leukemia cells. Biochem Int 18: 1077-1083, 1989.
42. Nishikawa K, Asaumi J, Kawasaki S, Kuroda M, Takeda Y and Hiraki Y: Influence of cepharanthin on the intracellular accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo. Anticancer Res 17: 3617-3621, 1997.
43. Tsuruo T, Iida H, Kitatani Y, Yokota K, Tsukagoshi S and Sakurai Y: Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells. Cancer Res 44: 4303-4307, 1984.
44. Tsuruo T, lida H, Naganuma K, Tsukagoshi S and Sakurai Y: Promotion by verapamil of vicristine responsiveness in tumor cell lines inherently resistant to the drugs. Cancer Res 43: 808-813, 1983.
45. Bodo J, Hunakova L, Kvasnicka P, Jakubikova J, Duraj J, Kasparkova J and Sedlak J: Sensitisation for cisplatin-induced apoptosis by isothiocyanate E-4IB leads to signalling pathways alterations. Br J Cancer 95: 1348-1353, 2006.
46. Ghoneum M and Gollapudi S: Modified arabinoxylan rice bran (MGN-3/Biobran) potentiates apoptosis in cancer cells induced by multiple anticancer agents in vitro. Seventh International Symposium on Predictive Oncology & Intervention Strategies. Nice, France, February 7-10, 2004.
47. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a system model. Cancer Cells 2: 275-280, 1990.
48. Martin SJ and Green DR: Apoptosis as a goal of cancer therapy. Curr Opin Oncol 6: 616-621, 1994.
49. Marchetti P, Mortier L, Beauvillain V and Formstecher P: Are mitochondria targets of anticancer drugs responsible for apoptosis? Ann Biol Clin (Paris) 60: 391-403, 2002.
50. Ghoneum M and Gollapudi S: Modified arabinoxylan rice bran (MGN-3/Biobran) enhances yeast-induced apoptosis in human breast cancer cells in vitro. Anticancer Res 25: 859-870, 2005.
51. Morse DL, Gray H, Payne CM and Gillies RJ: Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 4: 1495-504, 2005.
52. Ghoneum M and Jewett A: Production of tumor necrosis factora and interferon-g from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. Cancer Detect Prev 24: 314-324, 2000.